Selecta Biosciences (SELB) Tops Q4 EPS by 10c

Selecta Biosciences (NASDAQ: SELB) reported Q4 EPS of $0.03, $0.10 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $29.94 million versus the consensus estimate of $17.58 million.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
• Evogene (EVGN) Tops Q2 EPS by 15c